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ABSTRACT
Objective: The objective of the present research work is to carry out the pharmacokinetic studies of optimized matrix membrane moderated 
transdermal patch of bosentan monohydrate.
Materials and Methods: The matrix membrane moderated transdermal system was formulated using HPMC, HPMC K4M and E RLPO. In vitro 
diffusion studies were carried out using modified Franz diffusion cell and for the optimized transdermal patch, pharmacokinetic studies were carried 
out using New Zealand male rabbits. Plasma samples were quantified using high-performance liquid chromatography.
Results: The in vitro diffusion studies revealed that formulation F3 with HPMC K4M and E RLPO had controlled release up to 28 hrs, and a maximum 
of 95.02±2.68% drug was released. The release kinetics followed mixed order non-Fickian diffusion. The pharmacokinetic studies of the optimized 
patch revealed controlled release up to 45 hrs where a 2.2-fold increase in area under curve (AUC) and 3.8 times increase in mean residence time 
(MRT) were observed compared to oral route. The results were appeared to be significant at p≤0.05. The variation in half-life was found to be not 
statistically significant when compared between oral and transdermal routes.
Conclusion: The pharmacokinetic results concluded that the matrix membrane moderated transdermal system with extended AUC and MRT can 
enhance the bioavailability of bosentan monohydrate by minimizing the drug-related side effects in oral route.
Keywords: Bosentan monohydrate, In vitro diffusion studies, Pharmacokinetic studies.
INTRODUCTION
Bosentan monohydrate is the new generation endothelin receptor 
antagonist used to treat pulmonary arterial hypertension (PAH). PAH 
is characterized by elevations in the pulmonary arterial pressure and 
pulmonary vascular resistance leading to right ventricular failure and 
premature death. Bosentan monohydrate is an active dual endothelin-A 
and endothelin-B receptor antagonist and the first molecule of its class 
that was synthesized. Bosentan has been evaluated in PAH, and it has 
shown improvement in exercise capacity of the patient [1-3].
The oral therapy of bosentan monohydrate had drug-drug interactions 
including extensive hepatic metabolism and its oral bioavailability is 
50%; the pharmacokinetic properties have rationalized the drug for 
an alternative route [4]. As the drug is having short half-life of 5 hrs 
and pKa of 4.2 [5] transdermal drug delivery can be a better alternative. 
Transdermal drug delivery had peculiar advantages compared to oral 
route where the drug-induced toxicity can be moderated simply by 
removing the patch; it can be given to unconscious and nauseating 
patients. Gastrointestinal irritation can be avoided and treatment can 
be terminated at any point of time. Once in a week patch was proved to 
be more beneficial for the elderly and memory loss patients [6,7].
In our previous works, matrix membrane moderated transdermal system 
of bosentan monohydrate was formulated and the results depicted a 
prolonged in vitro release up to 28 hrs. The transdermal patches formulated 
were found to be durable and stable at accelerated climatic conditions [8].
The present investigation aimed at carrying out the pharmacokinetic 
studies for matrix membrane moderated transdermal system of 
bosentan monohydrate using New Zealand male rabbits as a model. 
The pharmacokinetic studies will give the basic idea about the 
pharmacokinetics of the modified dosage form by comparing with the 
oral route [9]. This can be used in designing of dosage regimen based 
upon half-life and mean residence time (MRT) of drug in the body.
MATERIALS AND METHODS
Materials
Bosentan monohydrate was gift sample received from MSN Laboratories, 
India. Hdroxypropyl methylcellulose (HPMC), hydroxypropyl 
methylcellulose (HPMC K4M) was gift sample received from Colorcon 
Asia Limited, and E RLPO were gift samples received from Zhaveri Pharma 
Chemicals, Mumbai. Dimethyl sulfoxide (DMSO), dichloromethane (DCM), 
high-performance liquid chromatography (HPLC) grade acetonitrile, 
methanol and water were purchased from SD Fine Chemicals, Mumbai.
Methods
The matrix membrane system consists of two layers. Where the 
primary layer is the drug reservoir layer and the secondary layer is the 
rate-controlling membrane.
Formulation of drug reservoir layer
The drug reservoir layer was formulated using a simple film-forming 
agent HPMC. A volume of 200 mg of HPMC was added to the solvent 
system of 10 ml (DCM:methanol 1:1) and kept for stirring for an hour. 
Bosentan monohydrate (60 mg) along with plasticizer propylene glycol 
(1.2 ml) were added and stirred for another 30 minutes. The dispersion 
was then poured into a mold of 4 cm × 4 cm2 and then kept for drying by 
covering with inverted funnel.
Formulation of rate-controlling membrane
Rate-controlling membranes were formulated using film-forming 
agent HPMC K4M and rate-controlling polymer E RLPO. HPMCK4M 
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and E RLPO were added to the 10 ml of solvent system (DCM:methanol 
in 1:1 ratio) and kept for stirring for 1 hr. Plasticizer propylene glycol 
20% of polymer concentration was added and stirring was continued 
for another 30 minutes. About 5% DMSO was added as penetration 
enhancer and stirred for another 15 minutes (Table 1). The dispersion 
was then poured into a mold and closed with inverted funnel for 
uniform drying. After 24 hrs, the dried membranes were collected and 
stored in a desiccator [10].
Drug content
The drug content studies were carried out using ultraviolet (UV)-
visible spectrophotometer at 272 nm. The formulation was added to 
phosphate buffer saline (PBS) (pH, 7.4) and kept for stirring for 24 hrs. 
The solution was then filtered and analyzed by making required 
dilutions
In vitro diffusion studies
Modified Franz diffusion cell was used for in vitro diffusion studies 
using PBS saline as media in receiver compartment [11]. The donor 
compartment contains transdermal system placed on dialysis 
membrane-150. The entire system was kept on magnetic stirrer at 
50 rpm. A sample of 3 ml was collected at regular intervals of time 
and sink conditions were maintained. Samples were analyzed using 
UV-visible spectrophotometer at 272 nm.
Estimation of bosentan monohydrate in rabbit plasma by reverse-
phase-HPLC
Chromatography was performed with Waters2695 HPLC provided with 
high-speed autosampler, column oven, degasser, and 2996 PDA detector 
with dual wavelength UV-visible detector operated at 273 nm with 
class Empower-2 software. ODS (C18 250 × 4.6, 5 µL) analytical column 
was used. Mobile phase used was 0.1% orthophosphoric acid and 
acetonitrile in the ratio of 20:80 v/v% and the pH was adjusted to 4.6 by 
using triethanolamine. Retention time for bosentan monohydrate was 
found to be 3.6 minutes and for etodolac (internal standard) retention 
time was found to be at 4.1 minutes.
Extraction procedure of bosentan monohydrate in plasma
250 μl of plasma, 50 μl of internal standard  and 10 ml of bosentan 
monohydrate were taken in a centrifuging tube with teflon-lined cap 
and 2 ml of acetonitrile was added and cyclomixing was done for 
15 minutes; then vertexed for 2 minutes to extract the drug into organic 
layer and finally centrifuged for 3 minutes at 3200 rpm speed. After 
centrifugation 10 µl of organic layer was directly injected into HPLC at 
a flow rate of 1.0 ml/min.
Pharmacokinetic studies
Studies were conducted according to Ethics Committee guidelines 
(CPCSEA Registration No.:1677/PO/Re/S/2012/CPCSEA). 
Pharmacokinetic studies for the optimized formulation were carried 
out using male New Zealand rabbits of weight 1.3-1.5 kg. Animals were 
kept under stabilized condition, provided with standard food, and 
kept for fasting for 24 hrs before commencing the study. Rabbits were 
divided into four groups (n=5): Group-I served as control group, Group I 
received vehicle used to make the drug suspension, for Group-III, 
bosentan monohydrate was given by oral route (11 mg/kg), and for 
Group-IV, formulated matrix membrane moderated transdermal patch 
of bosentan monohydrate was adhered to the skin. Hair on the sides of 
the vertebral column of the rabbit was removed and the transdermal 
patch was adhered with the help of a surgical adhesive tape. Blood 
sample of 1 ml was withdrawn from left marginal ear vein at time 
intervals of 0, 15, 30 minutes, 1, 2, 4, 8, 12, 20 and 24 hrs for oral and 
0, 30 minutes, 1, 2, 4, 6, 10, 15, 20, 25, 30, 35, 40, 45, 50 and 55 hrs 
for transdermal patch. The syringe used to draw blood was heparinized 
before using and plasma was separated immediately and stored in 
heparinized eppendrof and frozen at −20°C till analyzed further to 
estimate in vivo parameters.
Pharmacokinetic analysis
Pharmacokinetic parameters were estimated from mean plasma 
concentration versus time graph. Pharmacokinetic parameters such 
as Cmax, Tmax, half-life (t½), area under curve (AUC) and MRT were 
calculated using PKsolver an inbuilt program in Microsoft Excel 2010. 
Extravascular two compartment analysis was followed for transdermal 
patch [12] and one compartment for oral route.
Statistical analysis
All the results were done in triplicate and represented as mean 
± standard deviation. Statistical analysis like Student’s t-test was 
performed using Microsoft Excel 2010. Significant difference was 
considered at p≤0.05.
RESULTS AND DISCUSSION
The formulated matrix membrane moderated transdermal systems 
were found to have excellent pharmacotechnical properties and are 
viable to skin and the results were reported in our previous studies [8]. 
The drug content in all the transdermal patches was found to be in 
between 99.14±0.46 and 99.73±0.28%.
The in vitro cumulative drug release data revealed that the drug 
release followed controlled release pattern (Fig. 1). In case of F1, 
by the end of 14 hrs 95% of drug release was observed, by further 
increasing the concentration of HPMC K4M; no significant variation in 
the drug release pattern was observed. In case of F3, by the addition 
of E RLPO, maximum of 95.02±2.68% of drug release was observed by 
the end of 28 hrs with a significant variation from F1 and F2 (p<0.05). 
Further increasing the concentration of E RLPO in  F4 the release rate 
Table 1: Rate-controlling membrane by HPMC K4M
Formulation HPMC K4M (%) E RLPO (%) *Propylene glycol (%) *DMSO (%) DCM:Methanol (1:1)
F1 1 - 20 5 10 ml
F2 1.5 - 20 5 10 ml
F3 1 0.4 20 5 10 ml
F4 1 0.5 20 5 10 ml
*Quantities were taken in percentage weight of polymer. HPMC: Hydroxypropyl methylcellulose, DMSO: Dimethyl sulfoxide, DCM: Dichloromethane
Fig. 1: Cumulative percentage in vitro release profile of 
bosentan monohydrate through hydroxypropyl methylcellulose 
K4M rate-controlling membrane in phosphate buffer saline 
(mean±standard deviation, n=3)
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was delayed and by the end of 28 hrs only  85% of drug release was 
observed
The controlled release was mainly achieved by two mechanisms, 
i.e., by formation of matrix by E RLPO [13] polymer swelling 
and polymer chain relaxation by HPMC K4M. Polymer swelling 
will increase the diffusion path length of the drug and this will 
increase accordingly with the hydrophilic polymer concentration 
[14]. The drug release followed mixed order non-Fickian diffusion 
mechanism. Based on the interpretation of above results formulation 
F3 was optimized for further pharmacokinetic studies as there was 
95.04±2.68% of release by 24 hrs.
Pharmacokinetic studies
Pharmacokinetic modeling will give quantitative information regarding 
the plasma kinetic profile of drug which can be used simultaneously 
in pharmacodynamics modeling of the newly designed dosage form. 
Pharmacokinetic studies of orally administered and matrix membrane-
controlled transdermal system of bosentan monohydrate were 
estimated from mean plasma concentration versus time profile graph 
(Fig. 2).
The Cmax value in oral route was found to be 1.36±0.106 µg/ml at 
Tmax 2±0.221 hrs whereas in transdermal route, the Cmax value was 
0.77±0.013 µg/ml at Tmax 25±0.651 hrs. In the oral route the high Cmax 
and low Tmax values were due to rapid absorption of the drug whereas in 
case of transdermal route, the decrease in Cmax and increase in Tmax were 
observed which is due to the formulation factor and barrier properties 
of the skin. The elimination half-life was found to be 4.6±0.402 hrs in 
oral route whereas in transdermal it was found to be 5.53±1.114 hrs. 
No significant difference in half-life of the drug molecule was observed 
when compared to oral route. The AUC value in case of oral route was 
9.644±5.621 µg/ml/h whereas in case of transdermal delivery AUC 
was found to be 21.752±6.216 μg/ml/h. The MRT values were found 
to be 7.39±1.457 hrs for oral and 28.71±1.548 hrs for transdermal 
route (Table 2). Statistically significant difference was found (p≤0.05). 
Huge increase in AUC values by 2.25 times was observed when 
compared to oral route. The increase of MRT values by 3.8 times in 
transdermal system indicates the presence of drug for longer duration 
in the systemic circulation. Controlled delivery of drug into the systemic 
circulation and the reservoir effect after removal of the patch up to 
5 hrs were observed in the transdermal system. Controlled delivery of 
drug maintains the concentration of drug for longer duration thereby 
enhancing the bioavailability of drug. Drug-related side effects can 
also be minimized by avoiding the hepatic first-pass metabolism. 
Extravascular two compartmental analysis for transdermal route and 
one compartmental analysis for oral route were found to be best fit 
based on the regression values.
CONCLUSIONS
The pharmacokinetic studies concluded that the matrix membrane 
moderated transdermal patch of bosentan monohydrate can enhance 
the bioavailability. Extended AUC and MRT in transdermal route 
compared to oral route have further strengthened this assumption. 
There is a scope for further clinical pharmacokinetics studies. The 
transdermal patch was proved to be beneficial compared to oral route 
where drug-drug interactions can be minimized and they can enhance 
the patient’s compliance.
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